Different Presentations and Different Treatment Options in Blastic Plasmacytoid Dendritic Cell Neoplasms: A Case Series

Authors

  • Esra Cengiz Şanlıurfa Mehmet Akif İnan Education and Training Hospital, Şanlıurfa, Turkiye
  • Muruvvet Seda Aydin Ankara Bilkent City Hospital, Department of Hematology, Ankara, Turkiye
  • Ahmet K Gunes Ankara Etlik City Hospital, Department of Hematology, Ankara, Turkiye
  • Funda Ceran Ankara Bilkent City Hospital, Department of Hematology, Ankara, Turkiye
  • Simten Dagdas Ankara Bilkent City Hospital, Department of Hematology, Ankara, Turkiye
  • Gulsum Ozet Ankara Bilkent City Hospital, Department of Hematology, Ankara, Turkiye

DOI:

https://doi.org/10.18502/ijhoscr.v19i1.17829

Keywords:

Bendamustine; Blastic plasmacytoid dendritic cell neoplasm; Chemotherapy; Minimal residual disease; Stem cell transplantation

Abstract

Blastic plasmacytoid dendritic cell neoplasms (BPDCN) are rare, aggressive hematologic neoplasms. Awareness about this neoplasm has increased after it was defined as a clonal plasmacytoid dendritic cell disease under histiocytic/dendritic cell neoplasms in the World Health Organization 2022 classification of myeloid and Histiocytic/Dendritic Neoplasms1. Therapies include chemotherapy or immunotherapy2-4 though stem cell transplantation (SCT) is the best consolidative approach in eligible patients5. Here, we present one intensive therapy-ineligible and two intensive-therapy-eligible patients with different presentations of BPDCN.

 

Downloads

Published

2025-02-10

Issue

Volume (19) issue (1)

Section

Articles